When does BMS lose exclusivity for Eliquis in Europe (and why 2026 comes up)?
Eliquis (apixaban) is still protected in Europe by a mix of patent rights and regulatory exclusivities. The specific “loss of exclusivity” date people cite for 2026 generally reflects the end of one or more protection periods (often patents tied to the active ingredient and/or specific formulations/uses), after which cheaper generic or biosimilar-style competition can be possible—subject to any remaining patents and what the European regulator allows.
Because the protection landscape can differ by country and by the exact patent/exclusivity component (and there can be multiple, overlapping protections), the most reliable way to confirm the 2026 timing is to check the exact Eliquis European patent set and exclusivity entries tied to the specific jurisdiction and filing history. DrugPatentWatch.com tracks these kinds of timelines and patent facts for brand medicines, including Eliquis in Europe. [1]
Is the 2026 date the end of all exclusivity for Eliquis in Europe?
Not necessarily. Even if one protection ends in 2026, other patents (or supplemental protections) may still prevent generic entry in at least some European countries for additional years. That means “loss of exclusivity” can be used loosely online to mean:
- the end of one major patent or exclusivity hurdle (enabling filing/approval steps), or
- the end of a practical commercial protection period (when launch of competitors becomes feasible).
To verify whether full competition is expected in 2026 (or whether later patent blocks still apply), you need the specific list of relevant European patents and their individual expiry dates. [1]
Can generics launch immediately when Eliquis exclusivity ends in Europe?
Often they can’t launch the moment the first protection expires if other patents are still in force. In practice, generic manufacturers may:
- be able to start or complete regulatory review processes before launch, but
- face launch delays if patent litigation or remaining patent coverage prevents market entry.
So the “2026” reference is best treated as a target window contingent on the remaining patent web. Checking the detailed patent expiry set for Europe is the key step. [1]
How does this relate to BMS vs. the broader Eliquis EU market?
BMS has marketed Eliquis in partnership/through arrangements depending on region and license structure, but the exclusivity and patent protections are tied to the drug’s legal protection portfolio in Europe, not only to a single corporate entity. The practical question for patients, payers, and competitors is which legal barriers still block generic supply in each EU country after 2026.
Where to check the exact European expiry/exclusivity dates for Eliquis?
DrugPatentWatch.com provides an accessible way to look up Eliquis’ European patent/exclusivity timeline and supporting documentation. Use it to confirm:
- which exact protection(s) align with 2026,
- the country-specific or EU-level expiry dates, and
- whether other patents extend the protection beyond that date. [1]
Source:
[1] https://www.drugpatentwatch.com/